Theralase Technologies Inc. V.TLT

Could Theralase rise like ICCM today?

[N0taP00p]

Check out the news on this Israeli company called IceCure Medical, ICCM symbol.  Was at ~90 cents. Shot up to like $6+ after market and now in the $3-4 range, after announcing positive results of their kidney cancer treatment. Very different kind of treatment called cryoablation.  Would be nice if TLTFF got that kind of lift. Or more.

[toade1313]

"After announcing positive results".  Problem for TLT is that results have already been announced and we're at $.33. Something just doesn't feel right.

[ScienceFirst]

Toade1313 ... Again, lagging vision? If management added so much, on 4 occassions, after many FDA meetings and superior data despite 12 undertreated, ever thought that there could be a deal conditional to FDA BTD designation for example? There's no guarantee.  But that's a legiimate possibility.  And if so, then you'll have to wait.  Otherwise, binds could be an option

[ScienceFirst]

Toade1313 ... Again, lacking vision? If management added so much, on 4 occassions, after many FDA meetings and superior data despite 12 undertreated, ever thought that there could be a deal conditional to FDA BTD designation for example? There's no guarantee.  But that's a legitimate possibility.  And if so, then you'll have to wait.  Otherwise, bonds could be an

[99942Apophis]

You're absolutely correct toade1313 and up until a couple of months ago I didn't see that most if not all Theralase's accomplishments have only been released on stock outlets. By  keeping news releases to least expensive sources only current shareholders and those that know how to find social stock boards are exclusive buyers. Also be aware that even amongst us we debate and have

[N0taP00p]

I'm hoping it's just a lack of exposure to mainstream business media sources and nothing else. Even then a BT designation, insider buying and high CR numbers somehow don't seem to move the needle. 

[plantrader]

N0ta, Maybe the aspect that the founder was sanctioned by the OSC plays a role with bigger investors being hesitant? Their market cap seems so low vs their reported clinical progress. But we know the FDA can validate them and provide blatant credibility in one fell swoop by granting BTD/AA. Suddenly big investors will have amnesia about the past and will start loading up. 

[Longholder99]

Any investor who has done their homework will see that OSC witch hunt for what it was.  Deliberate and over the top targetting with a ridiculous sanction without precedent. Meaningless in the big picture beyond a sign that the status quo fears this change. 

[N0taP00p]

plantrader, It could be the under-treatment issue and waiting to see how the FDA reacts to that in the broader context. All in all, would be nice to have a mega booster NR in January. I'm keeping my hopes bottled up for now while desperately channeling my inner Eckhart Tolle for a $20 stock price next year.  Very conflicted way to live life, eh? 

[plantrader]

N0ta, I like your Tolle reference! I know exactly what you mean.  Maybe I'm having memory dyslexia right now lol but aren't the under treated #s still within the acceptable parameters? 

[N0taP00p]

from all the experts here, yes. You would think the FDA would agree. Just hoping it doesn't create an issue where they want ALL submitted data to be clinically exact to be considered for AA. In which case, we would need to wait some more. Maybe it's a good thing, given the significantly better results. After 10 years, what's another six months. 

[ScienceFirst]

Below, it confirms that the FDA can look at subgroups.  So data on our 25 patients will most probably be looked as 2 separate groups (first 12 undretreated versus optimized group (p#13-25)) Regarding ICCM, that have 37M shares.  In August 2021, IceCure Announces 8-for-1 Reverse Stock Split.  So they initially had 285M shares. Valuation is now 123M$US valuation.  2.5x more